Researchers have identified the best dosage ranges for five commonly used ADHD medications using data from thousands of patients. This new study, published in The Lancet Psychiatry, provides the most detailed look at how different doses affect both effectiveness and side effects.

To help patients and clinicians make informed decisions, an international research team led by Professor Samuele Cortese from the University of Southampton developed a free online tool based on these findings. Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental conditions, affecting about 5% of school-age children and 2% to 3% of adults.

Medication plays a crucial role in treatment, but current clinical guidelines often lack specific guidance on optimal dosages. The study analyzed data from 113 clinical trials involving over 25,000 participants. By employing an advanced method called dose-effect network meta-analysis, the researchers were able to estimate how different doses of each medication impact both effectiveness and side effects.

The findings revealed that dosage patterns varied significantly between medications and age groups. Dr. Mikail Nourredine from the University of Lyon noted, "Our study suggests that clinicians should avoid using low dosages as they may not be effective. If symptoms are not well controlled, higher doses might be necessary."

However, the research also found no evidence to support going beyond licensed maximum doses for better effectiveness. Higher doses were linked more frequently with increased side effects.

Professor Cortese emphasized, "Our study and tool can help in shared decision-making between clinicians, patients, and families when choosing the best dose. It's important that both patients and caregivers are involved."

The online tool helps show what to expect from each dosage level, allowing patients to understand why a particular dose has been chosen.

While these findings offer valuable guidance for ADHD treatment, it is essential to consider individual patient characteristics in personalized care plans. The study highlights the need for further research to tailor recommendations based on specific needs and responses.

Publication details: Mikail Nourredine et al., "Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis," The Lancet Psychiatry (2026). DOI: 10.1016/s2215-0366(26)00091-x.

Citation: ADHD Medications Show Dosage Sweet Spots, With Little Gain Above Limits (2026, May 15). Retrieved from https://medicalxpress.com/news/2026-05-adhd-medications-dosage-sweet-gain.html